Loading stock data…
$25.39-0.50 (-1.93%)
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally.
Schrödinger, Inc. in the Healthcare sector is trading at $25.39 with a market capitalization of $1.5B. Wall Street consensus targets $23.86 (7 analysts), implying a -6.0% move over the next 12 months. The stock is currently 25% below its 52-week high of $33.78, remaining 55.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $58.89M↑ | $58.59M↓ | $87.23M↑ | $54.32M↓ | $54.76M |
| Gross Profit | $32.43M↑ | $29.55M↓ | $57.29M↑ | $28.04M↑ | $26.16M |
| Operating Income | -$41.55M↑ | -$48.79M↓ | -$17.16M↑ | -$45.95M↑ | -$52.90M |
| Net Income | $5.97M↑ | -$60.03M↓ | $32.51M↑ | -$32.80M↑ | -$43.17M |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Af...